RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

NCT06173037 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Peritoneal Cancer
Fallopian Tube Cancer
Epithelial Ovarian Cancer

Interventions

DRUG: RC88

Sponsor

RemeGen Co., Ltd.